Success Metrics

Clinical Success Rate
66.7%

Based on 8 completed trials

Completion Rate
67%(8/12)
Active Trials
0(0%)
Results Posted
125%(10 trials)
Terminated
4(29%)

Phase Distribution

Ph phase_1
9
64%
Ph phase_3
1
7%
Ph phase_2
4
29%

Phase Distribution

9

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
9(64.3%)
Phase 2Efficacy & side effects
4(28.6%)
Phase 3Large-scale testing
1(7.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

57.1%

8 of 14 finished

Non-Completion Rate

42.9%

6 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(8)
Terminated(6)

Detailed Status

Completed8
Terminated4
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 19 (64.3%)
Phase 24 (28.6%)
Phase 31 (7.1%)

Trials by Status

terminated429%
withdrawn214%
completed857%

Recent Activity

0 active trials
Showing 5 of 14
terminatedphase_2

A Study of CP-751,871 in Patients With Recurrent Squamous Head and Neck Carcinoma

NCT00872404
completedphase_1

Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors

NCT00560235
terminatedphase_2

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

NCT00372996
withdrawnphase_2

Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer

NCT00678626
withdrawnphase_3

Study Of The Effect Of CP-751,871 In Combination With Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer

NCT00907504
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT00872404Phase 2

A Study of CP-751,871 in Patients With Recurrent Squamous Head and Neck Carcinoma

Terminated
NCT00560235Phase 1

Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors

Completed
NCT00372996Phase 2

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

Terminated
NCT00678626Phase 2

Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer

Withdrawn
NCT00907504Phase 3

Study Of The Effect Of CP-751,871 In Combination With Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer

Withdrawn
NCT00729833Phase 1

Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors

Terminated
NCT00474760Phase 1

Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors

Completed
NCT00927966Phase 1

RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms

Completed
NCT00147537Phase 1

Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer

Completed
NCT01653158Phase 1

CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies

Completed
NCT00926263Phase 1

A Pharmacokinetic And QT Study Of CP-751,871 In Healthy Subjects

Terminated
NCT00313781Phase 2

Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)

Completed
NCT00560573Phase 1

Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer

Completed
NCT01536145Phase 1

CP-751,871 Treatment For Patients With Multiple Myeloma

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14